jRCT2031240660招募中不适用
A Phase I study to evaluate the safety, tolerability, and pharmacokinetics of NTX-083 in healthy adult males.
未提供0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Other
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 50age old not（—）
- 性别
- Male
入选标准
- •A healthy Japanese male.
- •An individual who is age of 18 years or more and less than 50 years at the time of consent.
- •An individual who, in Eligibility Tests 1 and 2, has a systolic blood pressure >=90 mmHg and<=139 mmHg, a diastolic blood pressure >=50 mmHg and <=89 mmHg, and a heart rate >=55 and <=100 beats per minute.
- •An individual who has been provided sufficient explanation about participating in this clinical study, upon full understanding, and who has given his written consent of his own free will.
- •An individual who is able to be hospitalized and visit as outpatient the study site according to the study schedule.
- •An individual who has agreed to medically appropriate contraception (including prohibition of sperm donation) from the start of dosing of the study drug to 30 days after the final dosing. Medically appropriate contraception refers to not having sexual intercourse, undergone surgical sterilization such as vasectomy, use of intrauterine contraceptive devices, oral contraceptives, or condoms.
排除标准
- •An individual who, in the laboratory tests, vital signs, or 12-lead ECG results of the Eligibility Test 1 (Day -28 to Day -2) or Eligibility Test 2 (Day -1), is judged by the principal investigator or subinvestigator to have clinically abnormalities.
- •An individual who, in the 12-lead ECG results of the Eligibility Test 1 (Day -28 to Day -2) or Eligibility Test 2 (Day -1), is having QTcF value of >450 msec.
- •An individual who, in the Eligibility Test 1 (Day -28 to Day -2) or Eligibility Test 2 (Day -1), is having body weight of <50.0 kg.
- •An individual who, in the Eligibility Test 1 (Day -28 to Day -2) or Eligibility Test 2 (Day -1), is having BMI of <18.5 or >
- •An individual who, in the Eligibility Test 1 (Day -28 to Day -2), is having positive result of HBs antigen test, HBc antibody, HCV antibody test, HIV antigen/antibody test or qualitative syphilis test.
- •An individual who, in the medical interview of the investigator or subinvestigator and urine drug abuse testing of the Eligibility Test 1
- •(Day -28 to Day -2), have been determined to have a history of alcohol dependence or drug dependence.
- •An individual who, in kidney, liver, heart, central nervous/psychiatry system, etc., has a disease history considered to be unsuitable for this study (for example, renal failure, kidney dialysis, liver failure, myocardial infarction, angina, cardiomyopathy, heart failure, cerebral infarction, etc.).
- •An individual who has a history of disease or surgery (for example, gastrectomy, gastric binding surgery, gastric bypass surgery, etc.) that may affect the absorption of the investigational drug.
- •An individual who has a history or complication of drug allergy.
- •An individual who is not able to abstain from smoking during hospitalization.
- •An individual who has used any medicine within 7 days up to Day
- •However, quasi drugs are allowed to be used.
- •An individual who has taken grapefruit or St. John's Wort (Western Hypericum), or foods or beverages containing them within 7 days up to Day
- •An individual who has taken sulfonylurea (SU) within 12 weeks up to Day
- •An individual who has hospitalized or undergone invasive procedures accompanied by bleeding such as surgery, within 12 weeks up to Day
- •An individual who has participated in clinical research including other clinical trial, or taken other investigational drug, within 16 weeks up to Day
- •An individual who has donated component blood within 2 weeks up to Day 1, or who had at least 200 mL of blood drawn within 4 weeks, or who had at least 400 mL of blood drawn within 12 weeks.
- •An individual who has engaged in intense exercise (such as marathons, muscle training) within 2 weeks up to Day
- •An individual who, by Columbia Suicide Severity Rating Scale (C-SSRS) or by the clinical judgment of the investigator, has a risk of suicide (a score of 4 or 5 for suicidal ideation or behavior), who has attempted suicide in the past 6 months, or who has a history of intentional self-mutilation in the past 6 months.
- •Other, in the opinion of the investigator or subinvestigator, an individual who is judged to be inappropriate as a subject.
结局指标
主要结局
-
To evaluate the safety, tolerability, and pharmacokinetics of NTX-083 in healthy adult males.
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisChronic Suppurative Lung DiseaseRespiratory - Other respiratory disorders / diseasesInfection - Other infectious diseasesBronchiectasisACTRN12614001199606TB4 Sweden AB30
已完成
1 期
Phase I trial to evaluate the safety and tolerability of GDC-0214 in healthy volunteers and patients with mild asthmaAsthmaRespiratory - AsthmaACTRN12617001227381Genentech, Inc.102
已完成
1 期
Phase I trial to evaluate the safety and tolerability of GDC-4379 in healthy volunteers and patients with mild asthmaRespiratory - AsthmaAsthmaACTRN12619000227190Genentech128
已完成
不适用
A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose subcutaneous and intravenous administration of OMS721 in healthy subjectsautoimmune diseases10003816NL-OMON42466Omeros Corporation24
已完成
不适用
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of OMS1029 with single-dose intravenous and subcutaneous administration in healthy subjectsinflammatory autoimmune diseaseBerger's disease10003816NL-OMON53550Omeros Corporation48